SCHEMBL2956415

SCHEMBL2956415

O=C(O)NCCc1cccc(-c2nc(=O)c3ccccc3s2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.50
GABRA1 P14867 1/20 0.50
KDM4E B2RXH2 6/20 0.42
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
NPSR1 Q6W5P4 5/20 0.42
ALDH1A1 P00352 5/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
MAPT P10636 5/20 0.42
RXFP1 Q9HBX9 3/20 0.42
LMNA P02545 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
NFKB1 P19838 1/20 0.42
RECQL P46063 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046109 0.91 MIF (0.50) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2956303 0.90 ALDH1A1 (0.50) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2959722 0.90 MIF (0.53) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2962409 0.88 MAPT (0.48) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2958759 0.87 MIF (0.46) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2963167 0.87 MIF (0.46) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2953226 0.85 MIF (0.45) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL2956546 0.85 MIF (0.53) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL13199886 0.84 MIF (0.44) MIFGABRA1KDM4ENPC1RAB9A
SCHEMBL5015279 0.84 NPSR1 (0.54) MIFGABRA1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 US disclosed
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-26 US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF MIF, MORF4L1, FOXM1 MIF 1/4885GABRA1 3323/4885KDM4E 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.